Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III trial

Gladieff, L., Ferrero, A., De Rauglaudre, G., Brown, C., Vasey, P., Reinthaller, A., Pujade-Lauraine, E., Reed, N., Lorusso, D., Siena, S., Helland, H., Elit, L. and Mahner, S. (2012) Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III trial. Annals of Oncology, 23 5: 1185-1189. doi:10.1093/annonc/mdr441


Author Gladieff, L.
Ferrero, A.
De Rauglaudre, G.
Brown, C.
Vasey, P.
Reinthaller, A.
Pujade-Lauraine, E.
Reed, N.
Lorusso, D.
Siena, S.
Helland, H.
Elit, L.
Mahner, S.
Title Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III trial
Journal name Annals of Oncology   Check publisher's open access policy
ISSN 0923-7534
1569-8041
Publication date 2012-05
Year available 2011
Sub-type Article (original research)
DOI 10.1093/annonc/mdr441
Volume 23
Issue 5
Start page 1185
End page 1189
Total pages 5
Place of publication Oxford, United Kingdom
Publisher Oxford University Press
Collection year 2013
Language eng
Formatted abstract
Background: To perform a subset analysis of patients with partially platinum-sensitive recurrent ovarian cancer (ROC) who received either CD [carboplatin–pegylated liposomal doxorubicin (PLD)] or CP (carboplatin–paclitaxel) in the CALYPSO trial.
Patients and methods: CALYPSO, an international phase III, non-inferiority trial, enrolled women with ROC that relapsed >6 months following first- or second-line therapy. Patients were randomized to CD or CP. Patients with a treatment-free interval of >6 and ≤12 months were evaluated for progression-free survival (PFS), the primary end point of CALYPSO trial, and safety.
Results: A total of 344 partially platinum-sensitive patients were included (N = 161, CD and N = 183, CP). The hazard ratio for PFS was 0.73 (95% confidence interval: 0.58–0.90; P = 0.004 for superiority) in favor of CD. Median PFS times were 9.4 months (CD) and 8.8 months (CP). Toxicities more common with CP versus CD included grade 3/4 neutropenia (50% versus 39%; P = 0.015), grade 2 alopecia (86% versus 9%; P < 0.001), neuropathy and hypersensitivity reactions. Hand-foot syndrome was more common with CD; however, grade 3/4 reactions were low (one patient in each arm).
Conclusion: Carboplatin–PLD has a more favorable risk-benefit profile than CP in patients with partially platinum-sensitive ROC and should be considered an effective treatment option for these patients.
Keyword CALYPSO
Carboplatin
Paclitaxel
Partially platinum-sensitive
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ
Additional Notes First published online: October 5, 2011

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2013 Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 19 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 25 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 05 Jun 2012, 03:34:32 EST by System User on behalf of Medicine - Royal Brisbane and Women's Hospital